Form 8-K - Current report:
SEC Accession No. 0001437749-25-008765
Filing Date
2025-03-21
Accepted
2025-03-21 16:50:38
Documents
17
Period of Report
2025-03-21
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K vxrt20250321_8k.htm   iXBRL 8-K 33317
2 EXHIBIT 1.1 ex_792966.htm EX-1.1 224133
3 EXHIBIT 5.1 ex_792965.htm EX-5.1 7395
8 hinelogo.jpg GRAPHIC 22732
  Complete submission text file 0001437749-25-008765.txt   493196

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA vxrt-20250321.xsd EX-101.SCH 3579
5 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE vxrt-20250321_def.xml EX-101.DEF 11807
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE vxrt-20250321_lab.xml EX-101.LAB 15858
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE vxrt-20250321_pre.xml EX-101.PRE 12022
19 EXTRACTED XBRL INSTANCE DOCUMENT vxrt20250321_8k_htm.xml XML 2961
Mailing Address 170 HARBOR WAY, SUITE 300 SOUTH SAN FRANCISCO CA 94080
Business Address 170 HARBOR WAY, SUITE 300 SOUTH SAN FRANCISCO CA 94080 (650) 550-3500
Vaxart, Inc. (Filer) CIK: 0000072444 (see all company filings)

EIN.: 591212264 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-35285 | Film No.: 25761286
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)